Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YF476 in Barrett's Esophagus
NCT01298999Phase 2Completed
- Sponsor
- Columbia University
- Start
- Jun 2010
- Primary completion
- Dec 2017
- Modality
- Allosteric Modulators
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Barrett's esophagus comparing YF476 with Placebo (2 arms). Primary endpoints: Mean Ki67 Expression at 3 months and Number of Participants That Experienced Change in Any Biomarker Expression at 3 months. Started Jun 2010; status: completed.
02
Drugs
netazepide
03
Conditions
Barrett's esophagus
Beyond the preview
Go deeper on NCT01298999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01298999.